Literature DB >> 18057545

The rat oncogenome: comparative genetics and genomics of rat models of mammary carcinogenesis.

James D Shull1.   

Abstract

The Norway rat has for many years been widely used as an experimental model for the study of breast cancer etiology and prevention. Mammary cancer can be induced in rats by a variety of agents. The mammary cancers that develop in the various rat models resemble in many respects the breast cancers that develop in humans. It is now clear that significant differences exist between different rat models with respect to the genetic bases of susceptibility to mammary cancer as well as the somatic genetic events that are associated with development of mammary cancer. In this review I summarize our current understanding of the genetic and genomics of mammary cancer in the rat, compare and contrast the genetic/genomic features of different rat mammary cancer models and discuss the relevance of these models to breast cancer in humans.

Entities:  

Mesh:

Year:  2007        PMID: 18057545     DOI: 10.3233/bd-2007-28108

Source DB:  PubMed          Journal:  Breast Dis        ISSN: 0888-6008


  20 in total

1.  In vivo microdialysis sampling of adipokines CCL2, IL-6, and leptin in the mammary fat pad of adult female rats.

Authors:  Geetika Bajpai; Rosalia C M Simmen; Julie A Stenken
Journal:  Mol Biosyst       Date:  2014-01-24

2.  4-Vinylcyclohexene diepoxide (VCD) inhibits mammary epithelial differentiation and induces fibroadenoma formation in female Sprague Dawley rats.

Authors:  Laura E Wright; Jennifer B Frye; Ashley L Lukefahr; Samuel L Marion; Patricia B Hoyer; David G Besselsen; Janet L Funk
Journal:  Reprod Toxicol       Date:  2011-05-20       Impact factor: 3.143

Review 3.  Genetically engineered ERα-positive breast cancer mouse models.

Authors:  Sarah A Dabydeen; Priscilla A Furth
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

4.  Rat Mcs1b is concordant to the genome-wide association-identified breast cancer risk locus at human 5q11.2 and MIER3 is a candidate cancer susceptibility gene.

Authors:  Aaron D denDekker; Xin Xu; M Derek Vaughn; Aaron H Puckett; Louis L Gardner; Courtney J Lambring; Lucas Deschenes; David J Samuelson
Journal:  Cancer Res       Date:  2012-09-19       Impact factor: 12.701

5.  Exposure to estrogen and ionizing radiation causes epigenetic dysregulation, activation of mitogen-activated protein kinase pathways, and genome instability in the mammary gland of ACI rats.

Authors:  Kristy Kutanzi; Olga Kovalchuk
Journal:  Cancer Biol Ther       Date:  2013-05-10       Impact factor: 4.742

6.  Contrasting epistatic interactions between rat quantitative trait loci controlling mammary cancer development.

Authors:  Géraldine Piessevaux; Virginie Lella; Michèle Rivière; Daniel Stieber; Pierre Drèze; Josiane Szpirer; Claude Szpirer
Journal:  Mamm Genome       Date:  2008-12-04       Impact factor: 2.957

7.  Mapping of three genetic determinants of susceptibility to estrogen-induced mammary cancer within the Emca8 locus on rat chromosome 5.

Authors:  Beverly S Schaffer; Kristin M Leland-Wavrin; Scott G Kurz; John A Colletti; Nicole L Seiler; Christopher L Warren; James D Shull
Journal:  Cancer Prev Res (Phila)       Date:  2012-11-14

Review 8.  Rat models of 17β-estradiol-induced mammary cancer reveal novel insights into breast cancer etiology and prevention.

Authors:  James D Shull; Kirsten L Dennison; Aaron C Chack; Amy Trentham-Dietz
Journal:  Physiol Genomics       Date:  2018-01-26       Impact factor: 3.107

9.  Tissue-specific actions of the Ept1, Ept2, Ept6, and Ept9 genetic determinants of responsiveness to estrogens in the female rat.

Authors:  Scott G Kurz; Kimberly K Hansen; Mac T McLaughlin; Vijay Shivaswamy; Beverly S Schaffer; Karen A Gould; Rodney D McComb; Jane L Meza; James D Shull
Journal:  Endocrinology       Date:  2008-04-17       Impact factor: 4.736

10.  Tamoxifen induces regression of estradiol-induced mammary cancer in the ACI.COP-Ept2 rat model.

Authors:  Rachel L Ruhlen; Dana M Willbrand; Cynthia L Besch-Williford; Lixin Ma; James D Shull; Edward R Sauter
Journal:  Breast Cancer Res Treat       Date:  2008-09-09       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.